Business
Palisade Bio Launches New Corporate Website and Reiterates Commitment to Develop Therapeutics that Protect Intestinal Barrier Health
New website aligns with company’s mission to become a global leader in addressing diseases linked to intestinal barrier disruption and establishing new
About this update from Palisade Bio, Inc.
[{"type":"text","content":"New website aligns with company’s mission to become a global leader in addressing diseases linked to intestinal barrier disruption and establishing new standards of patient care in GI health\nCARLSBAD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the launch of its new corporate website, palisadebio.com and reiterates its commitment to all stakeholders by developing therapeutics that protect intestinal barrier health. “As we advance the development of our lead product candidate, bolster our growing body of data and build momentum towards value-driving milestones, it is important to align our website and brand to communicate the overarching vision we have for Palisade Bio,” commented Tom Hallam, Ph.D., Chief Executive Officer of Palisade Bio. “Protecting intestinal integrity is a cornerstone of preserving human health and our initial focus is on helping the millions of patients undergoing surgery every year overcome the myriad health conditions and complications associated with disruption of the gastrointestinal tract. The clinical data collected to-date continues to reinforce our confidence as we advance towards several key clinical and regulatory milestones ahead. I am excited for this next phase of evolution for Palisade Bio and the future of this impactful company.” The Company’s lead product candidate, LB1148, is a novel oral liquid formulation of the well-characterized digestive enzyme inhibitor, tranexamic acid (“TXA”), with potential to both reduce abdominal adhesions and help restore bowel function following surgery. The therapy is being developed for administration prior to surgeries that disrupt the intestinal epithelial barrier. Evidence suggests that the release of digestive proteases when the intestinal barrier is disrupted contributes to the temporary loss of normal gastrointestinal function and the formation of postoperative adhesions. By inhibiting the activity of these digestive proteases, LB1148 has the potential to prevent damage to GI tissues, reduce the formation of intraabdominal adhesions, and accelerate the time to the return of normal GI function which can shorten the duration of costly post-surgery hospital stays. Additionally, the company has...